Stemline Therapeutics (NASDAQ:STML) PT Lowered to $20.00 at HC Wainwright
Stemline Therapeutics (NASDAQ:STML) had its price objective decreased by HC Wainwright from $35.00 to $20.00 in a report issued on Tuesday morning, BenzingaRatingsTable reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
STML has been the topic of a number of other reports. BidaskClub cut shares of Stemline Therapeutics from a buy rating to a hold rating in a report on Friday, January 10th. Alliance Global Partners initiated coverage on shares of Stemline Therapeutics in a report on Monday, November 25th. They issued a buy rating and a $21.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Stemline Therapeutics in a report on Tuesday, December 24th. They issued an overweight rating and a $18.00 price target on the stock. Wedbush decreased their price objective on shares of Stemline Therapeutics from $17.00 to $14.00 and set an outperform rating for the company in a research report on Thursday, January 16th. Finally, Zacks Investment Research lowered shares of Stemline Therapeutics from a hold rating to a sell rating in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $20.00.
Shares of NASDAQ:STML traded down $0.05 during trading on Tuesday, reaching $6.88. The stock had a trading volume of 52,002 shares, compared to its average volume of 1,197,508. Stemline Therapeutics has a one year low of $6.01 and a one year high of $18.22. The company has a market capitalization of $344.89 million, a P/E ratio of -2.87 and a beta of 1.40. The firm’s 50-day simple moving average is $9.65 and its 200 day simple moving average is $11.13.
In related news, COO Kenneth Hoberman sold 13,228 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $10.37, for a total value of $137,174.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 13.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Empire Life Investments Inc. raised its position in shares of Stemline Therapeutics by 11.3% in the 4th quarter. Empire Life Investments Inc. now owns 572,223 shares of the biopharmaceutical company’s stock valued at $6,083,000 after purchasing an additional 57,954 shares during the last quarter. Rhenman & Partners Asset Management AB raised its position in shares of Stemline Therapeutics by 48.8% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 760,181 shares of the biopharmaceutical company’s stock valued at $8,081,000 after purchasing an additional 249,158 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Stemline Therapeutics in the 3rd quarter valued at approximately $479,000. California State Teachers Retirement System raised its position in shares of Stemline Therapeutics by 13.2% in the 3rd quarter. California State Teachers Retirement System now owns 69,843 shares of the biopharmaceutical company’s stock valued at $727,000 after purchasing an additional 8,164 shares during the last quarter. Finally, Eventide Asset Management LLC raised its position in shares of Stemline Therapeutics by 30.3% in the 3rd quarter. Eventide Asset Management LLC now owns 4,160,608 shares of the biopharmaceutical company’s stock valued at $43,312,000 after purchasing an additional 967,881 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: Depreciation
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.